November 27, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Presents Research Findings on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) at the Society for Neuro-Oncology (SNO) Annual Meeting

SymBio Pharmaceuticals Limited today announced its presentation of preclinical research findings supporting the potential of intravenous brincidofovir (IV BCV) as a treatment for malignant brain tumors (glioblastoma) in a poster session at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO), held November 19–23, 2025, in Honolulu, Hawaii, USA.

The data we presented are primarily based on mouse patient-derived xenograft (PDX) models established from glioblastoma tumors resected from the brains of multiple patients and subsequently engrafted, maintained, and serially passaged in mice. In orthotopic PDX models, BCV as a single agent demonstrated tumor growth inhibition and a survival benefit, and these effects were further enhanced when combined with the current standard of care, radiation and temozolomide. In addition, we confirmed the presence of BCV and its active metabolite (CDV-PP*) within tumor tissue following treatment. We believe these findings provide a strong rationale and valuable guidance as we progress toward clinical trial planning.

Statement from Masatoshi Hazama, Executive Officer and Chief Scientific Officer:
“We are very pleased to present at the prestigious Society for Neuro-Oncology findings from our research collaboration with the University of California, San Francisco (UCSF) that suggest the potential of IV BCV as a new therapeutic option for glioblastoma.”

Currently, in addition to glioblastoma, we are advancing development of BCV for head and neck cancer, EBV-positive gastric cancer, and NK/T-cell lymphoma, and these study findings provide valuable insights for the future development of BCV in the oncology field.

[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

Overview of the Presentation

- Title: In vivo characterization of preclinical efficacy of brincidofovir against glioblastoma
- Presenters: Sol Beccari, Tomoko Ozawa, David R. Raleigh, et al.

Presentation No.: EXTH-54

About the Society for Neuro-Oncology (SNO)

Established in 1996, SNO is one of the world's leading and most respected organizations dedicated to research on neuro-oncology and its therapies, bringing together medical professionals, researchers, healthcare providers, and stakeholders from the pharmaceutical industry. The Society serves as a vital forum for sharing research and acts as a driving force in the field of neuro-oncology, energizing the next generation of neuro-oncology scientists and clinicians.

About Malignant Brain Tumors (Glioblastoma)

A brain tumor that arises from glial cells is called a glioma. Certain types of glioma progress very rapidly and have a poor prognosis. For glioblastoma, the most malignant Grade 4 type, the median survival time after diagnosis is short, ranging from 2 to 18 months, with a five-year survival rate of less than 5%. Cancers with a five-year survival rate below 50% are classified as "intractable cancers." Glioblastoma, one such cancer, is estimated to affect approximately 2,000 people annually in Japan and 21,000 in Europe and the United States.

The current standard of care involves the use of temozolomide in combination with radiation therapy. The angiogenesis inhibitor bevacizumab (brand name: Avastin®) is also used. However, approximately half of all patients develop resistance to the standard therapy, temozolomide. There is no established treatment to overcome this resistance and there is a strong need for the development of new drugs.

*CDV-PP (cidofovir diphosphate) is converted from brincidofovir (a lipid conjugate of cidofovir) taken up by tumor cells and serves as the trigger for antitumor activity by inducing the DNA damage response.

BCV Business Strategy Built on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock its potential across three therapeutic areas. We are currently focusing our development resources on: (1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases. By pursuing development and commercialization globally across these three pillars, SymBio aims to maximize the value of the BCV franchise.